Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 12—December 2022
Research Letter

Omicron BA.5 Neutralization among Vaccine-Boosted Persons with Prior Omicron BA.1/BA.2 Infections

Rune M. Pedersen, Line L. Bang, Ditte S. Tornby, Lone W. Madsen, Dorte K. Holm, Thomas V. Sydenham, Isik S. Johansen, Thøger G. Jensen, Ulrik S. Justesen, and Thomas E. AndersenComments to Author 
Author affiliation: University of Southern Denmark, Odense, Denmark

Main Article


Characteristics of persons with and without Omicron BA.1/BA.2 breakthrough infection who received COVID-19 vaccines and booster doses, Denmark*

Characteristics Vaccines and booster Vaccines, booster, and Omicron breakthrough
Total no. persons
Sex, no. (%)
F 17 (70.8) 8 (66.6)
7 (29.2)
4 (33.4)
Median age, y (IQR)
41 (32–51)
47 (40–50)
Median no. days (IQR) between vaccination, infection, and sampling
Between first and second dose 29 (27–36) 28 (26–34)
Between second and third dose 152 (42–199) 200 (159–228)
Between third dose and sampling 29 (23–34) 90 (77–143)
Between third dose and infection NA 55 (31–109)
Between infection and sampling NA 33 (24–38)

*Participants received 3 doses of BNT162b2 (Pfizer-BioNTech,, 2 initial vaccines and a booster dose. IQR, interquartile range; NA, not applicable

Main Article

Page created: October 17, 2022
Page updated: November 21, 2022
Page reviewed: November 21, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.